



CV Template of KATRD International Conference 2021

Name	James Chih-Hsin Yang			
First Name	James Chih-Hsin	Last Name	Yang	
Country	Taiwan			
Organization	National Taiwan University Cancer Center			
Current Position	Professor, M.D., Ph.D			

Educational Background

Ph.D. Graduate Institute of Clinical Medicine College of Medicine, National Taiwan University	Sep1996-Jan 2000
M.D. School of Medicine, Medical College, National Taiwan University	Sep1979-June 1986

James Chih-Hsin Yang received his MD from National Taiwan University (NTU) in Taipei in 1986 and completed his PhD degree between 1996 and 2000 at the Graduate Institute of Clinical Medicine, NTU, in 2000. He first completed his internal medicine residency at the NTU Hospital, and between 1992 and 1995, he undertook medical oncology fellowship training at the National Cancer Institute at Bethesda, Maryland. He is currently the director and distinguished professor of the Graduate Institute of Oncology at National Taiwan University. He has been a staff member in the Department of Oncology at the University Hospital since 1995 and chair the Department of Oncology between 2015-2020. He was appointed as the superintendent of the National Taiwan University Cancer Center hospital in Aug 2020.

Professional Experiences

Superintendent, National Taiwan University Cancer Center	Aug 2020-
Director, Graduate Institute of Oncology, National Taiwan University	Aug 2015-
Professor, Graduate Institute of Oncology, Graduate Institute of Clinical Pharmacy Graduate Institute of Clinical Medicine College of Medicine, National Taiwan University	Aug 2009-
Staff Physician, Department of Medical Oncology, National Taiwan University Cancer Center	Aug 2020-
Visiting Physician, Department of Oncology, National Taiwan University Hospital	Aug 2020-



Professional Organizations

Member , American Association for Cancer Research
Member , American Society of Clinical Oncology
Member, International Society of Lung Cancer
Member , Chinese Society of Cancer , Taiwan
Member , Chinese Society of Hematology , Taiwan
Member , Chinese Society of Internal Medicine , Taiwan
Member, Lung Cancer Society, Taiwan

Main Scientific Publications

1. Awad MM, Gadgeel SM, Borghaei H, Patnaik A, **Yang JC**, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Altan M, Jalal SI, Panwalkar A, Gubens M, Sequist LV, Saraf S, Zhao B, Piperdi B, Langer CJ. Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC. **J Thorac Oncol.** 2021 Jan;16(1):162-168.
2. Park K, Özgüroğlu M, Vansteenkiste J, Spigel D, **Yang JCH**, Ishii H, Garassino M, de Marinis F, Szczesna A, Polychronis A, Uslu R, Krzakowski M, Lee JS, Calabrò L, Arén Frontera O, Xiong H, Bajars M, Ruisi M, Barlesi F. Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial. **J Thorac Oncol.** 2021 Apr 9:S1556-0864(21)01832-3.
3. Lung Cancer in Republic of China. Luo YH, Chiu CH, Scott Kuo CH, Chou TY, Yeh YC, Hsu HS, Yen SH, Wu YH, Yang JC, Liao BC, Hsia TC, Chen YM. **J Thorac Oncol.** 2021 Apr;16(4):519-527. 10.1016/j.jtho.2020.10.155..
4. Kim ES, Melosky B, Park K, Yamamoto N, **Yang JC**. EGFR tyrosine kinase inhibitors for EGFR mutation-positive non-small-cell lung cancer: outcomes in Asian populations **Future Oncol** 2021 Jun;17(18):2395-2408.
5. Yu HA, Paz-Ares LG, **Yang JC**, Lee KH, Garrido P, Park K, Kim JH, Lee DH, Mao H, Wijayawardana SR, Gao L, Hozak RR, Chao BH, Planchard D. Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR-mutant Non-small Cell Lung Cancer. **Clin Cancer Res.** 2021 Feb 15;27(4):992-1002.
6. **Yang JC***, Camidge DR, Yang CT, Zhou J, Guo R, Chiu CH, Chang GC, Shiah HS, Chen Y, Wang CC, Berz D, Su WC, Yang N, Wang Z, Fang J, Chen J, Nikolinakos P, Lu Y, Pan H, Maniam A, Bazhenova L, Shirai K, Jahanzeb M, Willis M, Masood N, Chowhan N, Hsia TC, Jian H, Lu S. Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial. **J Thorac Oncol.** 2020 Dec;15(12):1907-1918. **(Corresponding author)***
7. **Yang JC***, Cheng Y, Murakami H, Yang PC, He J, Nakagawa K, Kang JH, Kim JH, Hozak RR, Nguyen TS, Zhang WL, Enatsu S, Puri T, Orlando M. A Randomized Phase 2 Study of Gefitinib With or Without Pemetrexed as First-line Treatment in Nonsquamous Non-Small Cell Lung Cancer With EGFR Mutation: Final Overall Survival and Biomarker Analysis. **J Thorac Oncol.** 2020 Jan;15(1):91-100 (corresponding author)*
8. **Yang JCH**, Kim SW, Kim DW, Lee JS, Cho BC, Ahn JS, Lee DH, Kim TM, Goldman JW, Natale RB, Brown AP, Collins B, Chmielecki J, Vishwanathan K, Mendoza-Naranjo A, Ahn MJ. Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study. **J Clin Oncol.** 2020 Feb 20;38(6):538-547.
9. Hsu CC, Liao BC, Liao WY, Markovets A, Stetson D, Thress K, **Chih-Hsin Yang J*** .Exon 16-Skipping HER2 as a Novel Mechanism of Osimertinib Resistance in EGFR L858R/T790M-Positive Non-Small Cell Lung Cancer. **J Thorac Oncol.** 2020 Jan;15(1):50-61. **(corresponding author)***



10. **Yang JC***, Schuler M, Popat S, Miura S, Heeke S, Park K, Märten A, Kim ES. Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases. **J Thorac Oncol.** 2020 May;15(5):803-815. (**corresponding author**)*
11. Paik PK, Felip E, Veillon R, Sakai H, Cortot AB, Garassino MC, Mazieres J, Viteri S, Senellart H, Van Meerbeeck J, Raskin J, Reinmuth N, Conte P, Kowalski D, Cho BC, Patel JD, Horn L, Griesinger F, Han JY, Kim YC, Chang GC, Tsai CL, **Yang JC**, Chen YM, Smit EF, van der Wekken AJ, Kato T, Juraeva D, Stroh C, Bruns R, Straub J, John A, Scheele J, Heymach JV, Le X. Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. **N Engl J Med.** 2020 Sep 3;383:931-943. Online ahead of print. PMID: 32469185
12. Camidge DR, Kim HR, Ahn MJ, **Yang JCH**, Han JY, Hochmair MJ, Lee KH, Delmonte A, García Campelo MR, Kim DW, Griesinger F, Felip E, Califano R, Spira A, Gettinger SN, Tiseo M, Lin HM, Gupta N, Hanley MJ, Ni Q, Zhang P, Popat S. Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial. **J Clin Oncol.** 2020 Nov 1;38(31):3592-3603..
13. Rudin CM, Awad MM, Navarro A, Gottfried M, Peters S, Csösz T, Cheema PK, Rodriguez-Abreu D, Wollner M, **Yang JC**, Mazieres J, Orlandi FJ, Luft A, Gümüş M, Kato T, Kalemkerian GP, Luo Y, Ebianna V, Pietanza MC, Kim HR; KEYNOTE-604 Investigators. Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study. **J Clin Oncol.** 2020 Jul 20;38(21):2369-2379.. Online ahead of print. PMID: 32468956
14. Park K, Vansteenkiste J, Lee KH, Pentheroudakis G, Zhou C, Prabhash K, Seto T, Voon PJ, Tan DSW, **Yang JCH**, Wang J, Babu KG, Nakayama Y, Alip A, Chua KLM, Cheng JC, Senan S, Ahn YC, Kim TY, Ahn HK, Peters S, Yoshino T, Douillard JY. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS. **Ann Oncol.** 2020 Feb;31(2):191-201.
15. Sequist LV, Han JY, Ahn MJ, Cho BC, Yu H, Kim SW, **Yang JC**, Lee JS, Su WC, Kowalski D, Orlov S, Cantarini M, Verheijen RB, Mellempgaard A, Ottesen L, Frewer P, Ou X, Oxnard G. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. **Lancet Oncol.** 2020 Mar;21(3):373-386
16. Wu YL, Cheng Y, Zhou J, Lu S, Zhang Y, Zhao J, Kim DW, Soo RA, Kim SW, Pan H, Chen YM, Chian CF, Liu X, Tan DSW, Bruns R, Straub J, John A, Scheele J, Park K, **Yang JC**; INSIGHT Investigators. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial. **Lancet Respir Med.** 2020 Nov;8(11):1132-1143.
17. Oxnard GR, **Yang JC**, Yu H, Kim SW, Saka H, Horn L, Goto K, Ohe Y, Mann H, Thress KS, Frigault MM, Vishwanathan K, Ghorghiu D, Ramalingam SS, Ahn MJ. TATTON: a multi-arm, phase 1b trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer. **Ann Oncol.** 2020 Apr;31(4):507-516.
18. Tan DS, Leighl NB, Riely GJ, **Yang JC**, Sequist LV, Wolf J, Seto T, Felip E, Aix SP, Jonnaert M, Pan C, Tan EY, Ko J, Moody SE, Kim DW. Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study. **Lancet Respir Med.** 2020 Jun;8(6):561-572.
19. Hung PS, Huang MH, Kuo YY, **Yang JC*** The Inhibition of Wnt Restrain KRAS(G12V)-Driven Metastasis in Non-Small-Cell Lung Cancer. **Cancers (Basel).** 2020 Mar 31;12(4):837. (***Corresponding author**)